We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA hit an over-the-counter drug manufacturer in South China with a Form 483 for multiple violations, including missing operating procedures. Read More
The FDA confirmed that it has suspended inspections of Chinese drug manufacturing facilities until further notice in response to the coronavirus outbreak. Read More
Inventia Healthcare, a drugmaker headquartered in Mumbai, India, was slapped with a Form 483 for serious violations at its Thane, Maharashtra facility, including poor data integrity. Read More
The FDA hit a drug manufacturer in Dresden, Germany with a warning letter for serious violations, including a lack of API and stability testing. Read More
The FDA hit a Tijuana drug manufacturer with a warning letter for shoddy investigations into microbiological contamination and other serious violations observed during an agency inspection. Read More
A majority of consumers and physicians believe generic drugs are inferior in quality to branded products, FDA officials said at a National Press Club event in Washington, D.C., yesterday. Read More
Post-inspection Official Action Indicated (OAI) classifications by CDER and CBER have dropped sharply in recent years, according to the latest data from the FDA’s Inspection Classification Database. Read More